Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Yijing Li, Yang Liu, Yuxuan Che, Joseph McIntosh, Alexa A Jordan, Angela Leeming, Courtney L Andersen, Justin Cidado, Jingling Jin, Vivian Changying Jiang, Michael Wang

Blood (2021) 138 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2021-151609

Published: 2021

Journal Articles

Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Yijing Li, Yang Liu, Yuxuan Che, Alexa A Jordan, Joseph McIntosh, Angela Leeming, Courtney L Andersen, Justin Cidado, Jingling Jin, Vivian Changying Jiang, Michael Wang

Blood (2021) 138 (Supplement 1): 1181.

https://doi.org/10.1182/blood-2021-151062

Published: 2021

Journal Articles

Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma

Neeraj K Aryal, Anjana Sundarrajan, Scott Boiko, David Jenkins, Huayang Liu, Miika Ahdesmaki, Aurelie Bornot, Andrew Jarnuczak, Eric Miele, Ultan McDermott, Stephen Fawell, Lisa Drew, Larry H. Boise, Justin Cidado

Blood (2021) 138 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2021-151194

Published: 2021

Journal Articles

AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

Justine Roderick, Scott Boiko, Courtney L Andersen, Huiling Liang, Gregory Dowdell, Corinne Reimer, Lisa Drew, Danielle M Townsley, Justin Cidado

Blood (2021) 138 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2021-151725

Published: 2021

Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado

Blood (2021) 137 (21): 2947–2957.

https://doi.org/10.1182/blood.2020008528

Published: 2021

Includes: Supplemental data

Journal Articles

AZD4320 Is a Novel and Potent BCL-2/X L Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma

Yijing Li, MS, Yang Liu, PhD, Joseph McIntosh, BS, Alexa A Jordan, BS, Angela Leeming, Courtney L Andersen, PhD, Justin Cidado, PhD, Vivian Changying Jiang, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-140775

Published: 2020

Journal Articles

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Bing Z Carter, PhD, Po Yee Mak, Steven M. Kornblau, MD, Wenjing Tao, Yuki Nishida, MD PhD, Vivian Ruvolo, MS, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1271.

https://doi.org/10.1182/blood-2019-124826

Published: 2019

Journal Articles

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Courtney L Andersen, PhD, Amanda L Christie, MS, Alan Rosen, MS, Kim Maratea, DVM, PhD, Maureen Hattersley, Jon Travers, PhD, Justin Cidado, PhD, Sai Pulukuri, PhD, Jamal Saeh, PhD, Edwin Clark, PhD, Corinne Reimer, PhD, Jerome Mettetal, PhD

Blood (2019) 134 (Supplement_1): 1273.

https://doi.org/10.1182/blood-2019-129475

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock

Blood (2019) 133 (6): 566–575.

https://doi.org/10.1182/blood-2018-07-865527

Published: 2019

Includes: Supplemental data

Journal Articles

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Justin Cidado, PhD, Scott Boiko, MS, Theresa Proia, PhD, Haley Woods, MS, Omid Tavana, PhD, Maryann San Martin, MS, Adriana E. Tron, PhD, Wenlin Shao, PhD, Lisa Drew, PhD

Blood (2018) 132 (Supplement 1): 3946.

https://doi.org/10.1182/blood-2018-99-113423

Published: 2018

Journal Articles

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Brandon Chen, Wong Pamela, B.S., Daniel Auclair, PhD, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Christine M Dunham, PhD, Sagar Lonial, MD, Joseph Opferman, PhD, Shannon M Matulis, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 951.

https://doi.org/10.1182/blood-2018-99-113444

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD

Blood (2018) 132 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2018-99-114948

Published: 2018

Journal Articles

Overcoming MCL1 Resistance in Multiple Myeloma

Ka Tat Siu, PhD, Cherrie Huang, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Keertik Fulzele, PhD, Rosemary Soucy, Justin Cidado, PhD, Lisa Drew, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 472.

https://doi.org/10.1182/blood-2018-99-116377

Published: 2018

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

NARROW

Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma

AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

AZD4320 Is a Novel and Potent BCL-2/X L Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Overcoming MCL1 Resistance in Multiple Myeloma

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only